| pubmed-article:2211449 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2211449 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:2211449 | lifeskim:mentions | umls-concept:C0279516 | lld:lifeskim |
| pubmed-article:2211449 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:2211449 | lifeskim:mentions | umls-concept:C0108938 | lld:lifeskim |
| pubmed-article:2211449 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:2211449 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2211449 | pubmed:dateCreated | 1990-11-2 | lld:pubmed |
| pubmed-article:2211449 | pubmed:abstractText | The antibacterial activity of cefpodoxime proxetil was studied in an in-vitro model simulating doses of 100, 200 and 400 mg. Strains of Klebsiella spp. Proteus mirabilis, Escherichia coli, Streptococcus pyogenes, and Haemophilus influenzae were effectively reduced by a dose of 200 mg. While for Esch. coli no dose-activity relationship was observed--the maximal effect was achieved with a simulated dose of 100 mg--Staphylococcus aureus could be reduced effectively only by a simulated dose of 400 mg. The lower doses showed stepwise lower activities. Apart from broad spectrum beta-lactamases like SHV 2 or TEM 5 the presence of plasmid coded beta-lactamases in Esch. coli and H. influenzae did not affect the antibacterial activity of cefpodoxime proxetil. The results show that cefpodoxime was more active against Gram-negative bacteria than amoxycillin, and comparable activity to intramuscular cefotiam in the in-vitro model. | lld:pubmed |
| pubmed-article:2211449 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2211449 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2211449 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2211449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2211449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2211449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2211449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2211449 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2211449 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2211449 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:2211449 | pubmed:issn | 0305-7453 | lld:pubmed |
| pubmed-article:2211449 | pubmed:author | pubmed-author:WiedemannBB | lld:pubmed |
| pubmed-article:2211449 | pubmed:author | pubmed-author:JansenAA | lld:pubmed |
| pubmed-article:2211449 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2211449 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:2211449 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2211449 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2211449 | pubmed:pagination | 71-9 | lld:pubmed |
| pubmed-article:2211449 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2211449 | pubmed:meshHeading | pubmed-meshheading:2211449-... | lld:pubmed |
| pubmed-article:2211449 | pubmed:meshHeading | pubmed-meshheading:2211449-... | lld:pubmed |
| pubmed-article:2211449 | pubmed:meshHeading | pubmed-meshheading:2211449-... | lld:pubmed |
| pubmed-article:2211449 | pubmed:meshHeading | pubmed-meshheading:2211449-... | lld:pubmed |
| pubmed-article:2211449 | pubmed:meshHeading | pubmed-meshheading:2211449-... | lld:pubmed |
| pubmed-article:2211449 | pubmed:meshHeading | pubmed-meshheading:2211449-... | lld:pubmed |
| pubmed-article:2211449 | pubmed:meshHeading | pubmed-meshheading:2211449-... | lld:pubmed |
| pubmed-article:2211449 | pubmed:meshHeading | pubmed-meshheading:2211449-... | lld:pubmed |
| pubmed-article:2211449 | pubmed:meshHeading | pubmed-meshheading:2211449-... | lld:pubmed |
| pubmed-article:2211449 | pubmed:meshHeading | pubmed-meshheading:2211449-... | lld:pubmed |
| pubmed-article:2211449 | pubmed:meshHeading | pubmed-meshheading:2211449-... | lld:pubmed |
| pubmed-article:2211449 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2211449 | pubmed:articleTitle | Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model. | lld:pubmed |
| pubmed-article:2211449 | pubmed:affiliation | Pharmaceutical Microbiology, Bonn, FRG. | lld:pubmed |
| pubmed-article:2211449 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2211449 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2211449 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2211449 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2211449 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2211449 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2211449 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2211449 | lld:pubmed |
